Pharmaceutical Technology on MSN10d
MeiraGTx and Hologen launch AI-backed gene therapy venture
The venture aims to advance MeiraGTx’s Parkinson’s gene therapy through Phase III trials with up to $430m in funding from ...
MedCity News11d
Gene Therapy Biotech MeiraGTx Strikes Deal Bringing Generative AI to Pivotal Parkinson’s Trial
The Parkinson’s gene therapy, AAV-GAD, delivers the glutamic acid decarboxylase (GAD) gene into the subthalamic nucleus, a part of the brain key to motor control. It’s the same region targeted ...
Fierce Biotech11d
Hologen AI commits $430M to MeiraGTx Parkinson’s gene therapy
With MeiraGTx eyeing up how to take the drug through phase 3 and onto commercialization, Hologen has stepped in. The ...
pharmaphorum11d
MeiraGTx plans to take Parkinson's gene therapy into phase 3
Shares in the Anglo-US biotech rose sharply after the announcement, which came off the back of new data showing that the AAV-GAD gene therapy met targets for safety and efficacy in the MGT-GAD-025 ...
Hosted on MSN4mon
MIND Diet and Cognitive Decline; Gene Therapy for Parkinson's; Curbing MS Fatigue
(Nature Genetics) A high dose of the investigational gene therapy AAV-GAD, which delivers the glutamic acid decarboxylase (GAD) gene to the subthalamic nucleus to boost levels of GABA, was safe ...